During the last session, Day One Biopharmaceuticals Inc (NASDAQ:DAWN)’s traded shares were 0.6 million, with the beta value of the company hitting -1.30. At the end of the trading day, the stock’s price was $8.07, reflecting an intraday loss of -1.47% or -$0.12. The 52-week high for the DAWN share is $18.07, that puts it down -123.92 from that peak though still a striking 2.35% gain since the share price plummeted to a 52-week low of $7.88. The company’s market capitalization is $817.93M, and the average intraday trading volume over the past 10 days was 0.97 million shares, and the average trade volume was 1.18 million shares over the past three months.
Day One Biopharmaceuticals Inc (DAWN) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.22. DAWN has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.42.
Day One Biopharmaceuticals Inc (NASDAQ:DAWN) trade information
Day One Biopharmaceuticals Inc (DAWN) registered a -1.47% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -1.47% in intraday trading to $8.07, hitting a weekly high. The stock’s 5-day price performance is -1.94%, and it has moved by -14.47% in 30 days. Based on these gigs, the overall price performance for the year is -48.00%. The short interest in Day One Biopharmaceuticals Inc (NASDAQ:DAWN) is 17.02 million shares and it means that shorts have 11.31 day(s) to cover.
The consensus price target of analysts on Wall Street is $40, which implies an increase of 79.83% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $24 and $45 respectively. As a result, DAWN is trading at a discount of -457.62% off the target high and -197.4% off the low.
Day One Biopharmaceuticals Inc (DAWN) estimates and forecasts
In the rating firms’ projections, revenue will increase 24.25% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 31.49M as predicted by 8 analyst(s). Meanwhile, a consensus of 8 analyst(s) estimates revenue growth to 37.79M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -38.09%. While earnings are projected to return -38.39% in 2025.
DAWN Dividends
Day One Biopharmaceuticals Inc is due to release its next quarterly earnings on 2025-Feb-24. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Day One Biopharmaceuticals Inc (NASDAQ:DAWN)’s Major holders
Day One Biopharmaceuticals Inc insiders own 16.96% of total outstanding shares while institutional holders control 94.60%, with the float percentage being 113.93%. RA CAPITAL MANAGEMENT, L.P. is the largest shareholder of the company, while 249.0 institutions own stock in it. As of 2024-06-30, the company held over 7.87 million shares (or 9.0354% of all shares), a total value of $108.47 million in shares.
The next largest institutional holding, with 6.43 million shares, is of ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC’s that is approximately 7.3808% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $88.61 million.
Also, the Mutual Funds coming in first place with the largest holdings of Day One Biopharmaceuticals Inc (DAWN) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and SPDR SERIES TRUST-SPDR(R) S&P(R) Biotech ETF . Data provided on Dec 31, 2024 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 2.24 shares. This amounts to just over 2.21 percent of the company’s overall shares, with a $18.04 million market value. The same data shows that the other fund manager holds slightly less at 1.69, or about 1.67% of the stock, which is worth about $13.66 million.
